Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RALNOVO: Raltegravir Effect on Persistent de Novo HIV Infection
NCT02611895Completed
- Sponsor
- CHU Montpellier
- Start
- Mar 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by CHU Montpellier. Primary endpoint: Frequency of virologic responders harbouring intracytoplasmic HIV DNA in their peripheral blood CD4+ T cells at 1 day. Started Mar 2015; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02611895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611895.